Ameriprise
TNDM icon

Ameriprise’s Tandem Diabetes Care TNDM Stock Holding History

Ameriprise’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.32M Sell
121,150
-7,570
-6% -$164K ﹤0.01% 2880
2025
Q4 		$2.83M Sell
128,720
-40,010
-24% -$722K ﹤0.01% 2813
2025
Q3 		$2.05M Sell
168,730
-250,307
-60% -$3.39M ﹤0.01% 2992
2025
Q2 		$7.81M Buy
419,037
+31,150
+8% +$617K ﹤0.01% 2005
2025
Q1 		$7.22M Buy
387,887
+42,206
+12% +$1.24M ﹤0.01% 2019
2024
Q4 		$12.5M Sell
345,681
-525,159
-60% -$17.8M ﹤0.01% 1641
2024
Q3 		$36.9M Sell
870,840
-609,934
-41% -$25.9M 0.01% 993
2024
Q2 		$59.6M Buy
1,480,774
+688,746
+87% +$28.7M 0.02% 712
2024
Q1 		$28.1M Buy
792,028
+478,474
+153% +$12.8M 0.01% 1101
2023
Q4 		$9.35M Buy
313,554
+40,675
+15% +$844K ﹤0.01% 1837
2023
Q3 		$5.66M Sell
272,879
-12,072
-4% -$332K ﹤0.01% 2184
2023
Q2 		$6.99M Sell
284,951
-2,536
-0.9% -$81.6K ﹤0.01% 2088
2023
Q1 		$11.7M Buy
287,487
+71,579
+33% +$2.96M ﹤0.01% 1644
2022
Q4 		$9.69M Sell
215,908
-2,686
-1% -$122K ﹤0.01% 1762
2022
Q3 		$10.5M Buy
218,594
+8,487
+4% +$465K ﹤0.01% 1638
2022
Q2 		$12.4M Sell
210,107
-468,122
-69% -$38.4M ﹤0.01% 1555
2022
Q1 		$78.9M Buy
678,229
+486,762
+254% +$56.8M 0.02% 620
2021
Q4 		$29.1M Buy
191,467
+20,335
+12% +$2.74M 0.01% 1137
2021
Q3 		$20.4M Buy
171,132
+87,048
+104% +$9.59M 0.01% 1249
2021
Q2 		$8.17M Sell
84,084
-162,385
-66% -$14.5M ﹤0.01% 2090
2021
Q1 		$21.8M Sell
246,469
-118,224
-32% -$11M 0.01% 1258
2020
Q4 		$34.9M Sell
364,693
-1,604
-0.4% -$165K 0.01% 908
2020
Q3 		$40.4M Buy
366,297
+18,838
+5% +$1.98M 0.02% 721
2020
Q2 		$34.4M Buy
347,459
+21,682
+7% +$1.73M 0.01% 768
2020
Q1 		$21M Buy
325,777
+96,603
+42% +$6.77M 0.01% 910
2019
Q4 		$13.6M Buy
229,174
+184,425
+412% +$11.4M 0.01% 1496
2019
Q3 		$2.64M Sell
44,749
-7,039
-14% -$449K ﹤0.01% 2562
2019
Q2 		$3.34M Buy
51,788
+10,528
+26% +$679K ﹤0.01% 2478
2019
Q1 		$2.62M Sell
41,260
-278,464
-87% -$14.6M ﹤0.01% 2612
2018
Q4 		$12.1M Buy
319,724
+29,048
+10% +$1.03M 0.01% 1435
2018
Q3 		$12.5M Sell
290,676
-190,789
-40% -$6.66M ﹤0.01% 1700
2018
Q2 		$10.6M Buy
+481,465
New +$5.92M ﹤0.01% 1691
2017
Q4 		– Sell
-1,000
Closed -$7K – 3734
2017
Q3 		$7K Sell
1,000
-1
-0.1% -$6 ﹤0.01% 3664
2017
Q2 		$8K Buy
+1,001
New +$9.25K ﹤0.01% 3716
2015
Q3 		– Sell
-4,087
Closed -$443K – 3942
2015
Q2 		$443K Sell
4,087
-8,142
-67% -$1.01M ﹤0.01% 3496
2015
Q1 		$1.54M Buy
12,229
+6,130
+101% +$797K ﹤0.01% 2714
2014
Q4 		$775K Buy
6,099
+26
+0.4% +$3.6K ﹤0.01% 2968
2014
Q3 		$815K Buy
6,073
+1
+0% +$140 ﹤0.01% 2886
2014
Q2 		$987K Sell
6,072
-158
-3% -$26.9K ﹤0.01% 2778
2014
Q1 		$1.38M Buy
6,230
+950
+18% +$242K ﹤0.01% 2611
2013
Q4 		$1.36M Buy
+5,280
New +$1.21M ﹤0.01% 2574

Other funds holding TNDM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ameriprise's TNDM Position: Q1 2026 in Review

Ameriprise reduced its Tandem Diabetes Care (TNDM) stake by 5.9% in Q1 2026, selling an estimated $164K and leaving 121,150 shares worth $2.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2880.

Ameriprise first reported a position in TNDM in Q4 2013 and has held it in 41 quarters since. The position peaked at $78.9M in Q1 2022. 272 funds tracked by Wall St. Rank hold TNDM as of Q1 2026.

  • Ameriprise held 121,150 shares of Tandem Diabetes Care worth $2.32M as of Q1 2026.
  • Ameriprise sold 7,570 Tandem Diabetes Care shares in Q1 2026, an estimated $164K.
  • Tandem Diabetes Care made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2880 holding.
  • Ameriprise first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 41 quarters since.
  • Ameriprise's Tandem Diabetes Care position peaked at $78.9M in Q1 2022.
  • 272 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.